Effect of glycosoaminoglycans on the clinical course of diabetic nephropathy at the stage of microalbuminuria in patients with type 2 diabetes mellitus
Aim. To evaluate clinical efficiency of sulodexide (glycosoaminoglycan) for the treatment of patients with type 2 diabetes mellitus (DM2) and diabeticnephropathy (DN) at the stage of microalbuminuria (MAU). Materials and methods. A total of 30 patients with DM2 and MAU were examined 15 of whom wer...
Guardado en:
| Autores principales: | , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN RU |
| Publicado: |
Endocrinology Research Centre
2010
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/e156276ee1b8436492a7037ca5257bbd |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:e156276ee1b8436492a7037ca5257bbd |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:e156276ee1b8436492a7037ca5257bbd2021-11-14T09:00:15ZEffect of glycosoaminoglycans on the clinical course of diabetic nephropathy at the stage of microalbuminuria in patients with type 2 diabetes mellitus2072-03512072-037810.14341/2072-0351-5671https://doaj.org/article/e156276ee1b8436492a7037ca5257bbd2010-06-01T00:00:00Zhttps://www.dia-endojournals.ru/jour/article/view/5671https://doaj.org/toc/2072-0351https://doaj.org/toc/2072-0378Aim. To evaluate clinical efficiency of sulodexide (glycosoaminoglycan) for the treatment of patients with type 2 diabetes mellitus (DM2) and diabeticnephropathy (DN) at the stage of microalbuminuria (MAU). Materials and methods. A total of 30 patients with DM2 and MAU were examined 15 of whom were given sulodexide (200 mg daily) for 6 months.The following parameters were measured before, 3 and 6 months after the onset of therapy: HbA1c level, biochemical characteristics, highly sensitiveCRB, MAU in morning urine samples, soluble intercellular and vascular cell adhesion molecules-1, blood coagulation and anticoagulation factors(PTI, fibrinogen, thrombin time, coagulation factors VII, VIII, X, Willebrand factor), tissue plasminogen activator, and its inhibitor. Results. Sulodexide produced significant positive effect on albumin excretion in urine. It exerted antithromotic and profibrinolytic action and improvedendothelial function. Taken together, these properties of sulodexide give reason to recommend it as a protector of different vascular segments. Conclusion. Significant positive effect of sulodexide on albumin excretion in urine coupled to its multifactor activity, convenience of therapeutic application,low risk of complications, good tolerability, and safety in aged patients with DM2 permit to consider it as a promising tool for the treatmentof DM2 with MAU.Iya Vladimirovna SemenovaLyudmila Alexandrovna ChugunovaAlexander Viktorovich Il'inAnna Petrovna KnyazevaLidia Dmitrievna ChirkovaMarina Vladimirovna ShestakovaIvan Ivanovich DedovEndocrinology Research Centrearticledibetes mellitusdiabetic nephropathymicroalbuminuriaheparin sulfatesulodexideNutritional diseases. Deficiency diseasesRC620-627ENRUСахарный диабет, Vol 13, Iss 2, Pp 34-39 (2010) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN RU |
| topic |
dibetes mellitus diabetic nephropathy microalbuminuria heparin sulfate sulodexide Nutritional diseases. Deficiency diseases RC620-627 |
| spellingShingle |
dibetes mellitus diabetic nephropathy microalbuminuria heparin sulfate sulodexide Nutritional diseases. Deficiency diseases RC620-627 Iya Vladimirovna Semenova Lyudmila Alexandrovna Chugunova Alexander Viktorovich Il'in Anna Petrovna Knyazeva Lidia Dmitrievna Chirkova Marina Vladimirovna Shestakova Ivan Ivanovich Dedov Effect of glycosoaminoglycans on the clinical course of diabetic nephropathy at the stage of microalbuminuria in patients with type 2 diabetes mellitus |
| description |
Aim. To evaluate clinical efficiency of sulodexide (glycosoaminoglycan) for the treatment of patients with type 2 diabetes mellitus (DM2) and diabeticnephropathy (DN) at the stage of microalbuminuria (MAU). Materials and methods. A total of 30 patients with DM2 and MAU were examined 15 of whom were given sulodexide (200 mg daily) for 6 months.The following parameters were measured before, 3 and 6 months after the onset of therapy: HbA1c level, biochemical characteristics, highly sensitiveCRB, MAU in morning urine samples, soluble intercellular and vascular cell adhesion molecules-1, blood coagulation and anticoagulation factors(PTI, fibrinogen, thrombin time, coagulation factors VII, VIII, X, Willebrand factor), tissue plasminogen activator, and its inhibitor. Results. Sulodexide produced significant positive effect on albumin excretion in urine. It exerted antithromotic and profibrinolytic action and improvedendothelial function. Taken together, these properties of sulodexide give reason to recommend it as a protector of different vascular segments. Conclusion. Significant positive effect of sulodexide on albumin excretion in urine coupled to its multifactor activity, convenience of therapeutic application,low risk of complications, good tolerability, and safety in aged patients with DM2 permit to consider it as a promising tool for the treatmentof DM2 with MAU. |
| format |
article |
| author |
Iya Vladimirovna Semenova Lyudmila Alexandrovna Chugunova Alexander Viktorovich Il'in Anna Petrovna Knyazeva Lidia Dmitrievna Chirkova Marina Vladimirovna Shestakova Ivan Ivanovich Dedov |
| author_facet |
Iya Vladimirovna Semenova Lyudmila Alexandrovna Chugunova Alexander Viktorovich Il'in Anna Petrovna Knyazeva Lidia Dmitrievna Chirkova Marina Vladimirovna Shestakova Ivan Ivanovich Dedov |
| author_sort |
Iya Vladimirovna Semenova |
| title |
Effect of glycosoaminoglycans on the clinical course of diabetic nephropathy at the stage of microalbuminuria in patients with type 2 diabetes mellitus |
| title_short |
Effect of glycosoaminoglycans on the clinical course of diabetic nephropathy at the stage of microalbuminuria in patients with type 2 diabetes mellitus |
| title_full |
Effect of glycosoaminoglycans on the clinical course of diabetic nephropathy at the stage of microalbuminuria in patients with type 2 diabetes mellitus |
| title_fullStr |
Effect of glycosoaminoglycans on the clinical course of diabetic nephropathy at the stage of microalbuminuria in patients with type 2 diabetes mellitus |
| title_full_unstemmed |
Effect of glycosoaminoglycans on the clinical course of diabetic nephropathy at the stage of microalbuminuria in patients with type 2 diabetes mellitus |
| title_sort |
effect of glycosoaminoglycans on the clinical course of diabetic nephropathy at the stage of microalbuminuria in patients with type 2 diabetes mellitus |
| publisher |
Endocrinology Research Centre |
| publishDate |
2010 |
| url |
https://doaj.org/article/e156276ee1b8436492a7037ca5257bbd |
| work_keys_str_mv |
AT iyavladimirovnasemenova effectofglycosoaminoglycansontheclinicalcourseofdiabeticnephropathyatthestageofmicroalbuminuriainpatientswithtype2diabetesmellitus AT lyudmilaalexandrovnachugunova effectofglycosoaminoglycansontheclinicalcourseofdiabeticnephropathyatthestageofmicroalbuminuriainpatientswithtype2diabetesmellitus AT alexanderviktorovichilin effectofglycosoaminoglycansontheclinicalcourseofdiabeticnephropathyatthestageofmicroalbuminuriainpatientswithtype2diabetesmellitus AT annapetrovnaknyazeva effectofglycosoaminoglycansontheclinicalcourseofdiabeticnephropathyatthestageofmicroalbuminuriainpatientswithtype2diabetesmellitus AT lidiadmitrievnachirkova effectofglycosoaminoglycansontheclinicalcourseofdiabeticnephropathyatthestageofmicroalbuminuriainpatientswithtype2diabetesmellitus AT marinavladimirovnashestakova effectofglycosoaminoglycansontheclinicalcourseofdiabeticnephropathyatthestageofmicroalbuminuriainpatientswithtype2diabetesmellitus AT ivanivanovichdedov effectofglycosoaminoglycansontheclinicalcourseofdiabeticnephropathyatthestageofmicroalbuminuriainpatientswithtype2diabetesmellitus |
| _version_ |
1718429618581536768 |